the future of tyrosine kinase inhibitors for melanoma and open questions
Published 7 years ago • 340 plays • Length 2:23Download video MP4
Download video MP3
Similar videos
-
2:54
pembrolizumab or egfr tyrosine kinase inhibitors in nsclc?
-
1:13:43
highlights from bruton’s tyrosine kinase inhibitors
-
4:09
tyrosine kinase inhibitors in egfr-mutant nsclc: when and who?
-
23:37
kinase inhibitors and immunomodulatory drugs - what does the future hold for lymphomas?
-
1:18:47
"tkis: tyrosine kinase inhibitors & neuroendocrine tumors" • 2024 lacnets event • march 29, 2024
-
1:00:31
webinar wednesdays - tyrosine kinase inhibitors & pkd
-
1:37
inhibition of abl tyrosine kinases shows potential for metastatic cancer treatment
-
5:25
bruton tyrosine kinase inhibitors
-
4:58
hcc whiteboard #2: the mechanisms of action of tyrosine kinase inhibitors
-
15:50
interpreting sakinorva results (intp)
-
5:04
gefitinib: inhibitor of egfr tyrosine kinase mutants in nsclc
-
4:07
understanding resistance to combined braf and mek inhibiton in melanoma and the significance of cdk4
-
1:03
what can be achieved with triple combination therapy phase i trial for metastatic melanoma
-
6:45
anti-pd1 or tyrosine kinase inhibitors?
-
8:41
use of vegf-targeted tyrosine kinase inhibitors
-
2:01
antibody arrays to assess resistance to tyrosine kinase inhibitors | protocol preview
-
0:59
eric vachon on the effect of complexity on adherence with kinase inhibitors
-
1:35
micrornas' role in tyrosine kinase inhibitor resistance and their potential as indicators
-
1:06
evaluating the suitability of checkpoint inhibitors with biomarkers in patients with melanoma
-
1:27
dr. grigg on frontline tyrosine kinase inhibitors in rcc
-
4:14
key melanoma highlights from asco 2024, including relativity-048 and nadina trials
-
1:31
brim-3 trial in melanoma: prognostic factors of overall survival and the issue of salvage therapies